Your session is about to expire
← Back to Search
JAB-3312 for Cancer
Study Summary
This trial is testing a new drug, JAB-3312, to see what the maximum tolerated dose is. JAB-3312 will be taken once daily orally, and the study will last 21 days per cycle. They expect to enroll 24 people in this phase of the study.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have had lung conditions that needed steroids or procedures to remove fluid.I am 18 years old or older.I do not have any serious or active infections.My cancer has worsened despite treatment or there's no standard treatment for it.I have had a bone marrow or organ transplant from another person.I am fully active or can carry out light work.I have brain metastases but they are stable and treated.I have a severe autoimmune disease or need high-dose steroids.I haven't taken any cancer drugs or experimental drugs in the last 28 days, except for prostate cancer treatment.I haven't had radiation therapy in the last 28 days and don't expect to need it soon.I have no major side effects from previous treatments.You have tested positive for hepatitis B, hepatitis C, or HIV in the past.You must have at least one detectable tumor that meets specific guidelines for size and assessment.Patients must have at least one specific area of the body that can be measured according to a certain standard.I have a history of serious eye inflammation or blood vessel problems.I am 18 years old or older.My organs are functioning well.I have not had a blood transfusion in the last 2 weeks.My cancer has worsened despite treatment or there's no standard treatment for it.I am fully active or can carry out light work.My organs are functioning well.
- Group 1: JAB-3312
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What aims does this research endeavor hope to accomplish?
"This medical trial will be monitored for a period of two years, with the purpose of discovering an effective dosage rate (RP2D) of JAB-3312. Secondary objectives involve tracking adverse events and their severity, calculating plasma concentration time curves, and measuring peak concentrations in patients' blood samples."
Has JAB-3312 been sanctioned by the FDA?
"Our team's assessment of JAB-3312 safety is rated 1 due to the fact that there are limited data points indicating its efficacy and security in Phase 1."
What is the geographic scope of this experiment?
"At the moment, 4 separate clinical trial sites are running this research. These locales include Nashville, Denver and Houston as well as a quartet of additional facilities. For participants' convenience, it is best to choose the test centre closest to your home to reduce travelling demands."
Are there still vacancies available for participants in this research endeavor?
"Affirmative. According to the information available on clinicaltrials.gov, this study is presently enrolling participants who were initially posted in September 2019 and last updated in March 2022. The trial requires the recruitment of 24 patients from 4 distinct sites."
What is the current quota for enrolling participants in this clinical trial?
"This clinical trial necessitates 24 participants who meet the inclusion requirements. Those interested may join at either Tennessee Oncology, PLLC in Nashville or HealthONE Clinic Services Oncology-Hematology in Denver."
Share this study with friends
Copy Link
Messenger